Jubilant Biosys announces the appointment of Mr. Giuliano Perfetti as new CEO

Mr. Perfetti has more than 20 years of experience across diverse businesses and global markets with expertise in Strategy, Sales, Marketing and Business Development.
By: Jubilant Biosys
SAN DIEGO - Sept. 14, 2021 - PRLog -- Jubilant Biosys Limited announced the appointment of Giuliano Perfetti as its Chief Executive Officer.

Mr. Perfetti has led business transformation and expansion programs working in reputed names including Accenture and AstraZeneca among others. Prior to joining Jubilant Biosys, Mr. Perfetti was associated with Fabbrica Italiana Sintetici (F.I.S) as Chief Commercial Officer and was responsible for strategizing and executing the company's growth plan and ramping up the global scale-up and commercial service business.

"I am thrilled to be joining the Jubilant Bhartia Group at such a pivotal time of growth and investment bringing a fully integrated offering from Drug Discovery to Development and Commercial Production" said Mr. Giuliano Perfetti on his appointment.

Commenting on his joining, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia CoChairman and Managing Director Jubilant Pharmova said "Jubilant Biosys is delighted to have Giuliano come on board as we make rapid progress in expanding our drug discovery services (https://www.jubilantbiosys.com/integrated-drug-discovery-...) and CDMO business through investments in infrastructure and new capacity."

About Jubilant Biosys Limited:

Jubilant Biosys, a subsidiary of Jubilant Pharmova Limited, an integrated global pharmaceutical company, has a presence in Bengaluru and Noida in India. Jubilant Biosys offers contract research & development services for global pharmaceutical innovators. Jubilant Biosys has demonstrated expertise in functional services in chemistry including computational, medicinal/ synthetic chemistry, PR&D and GMP scale-up capabilities up to phase II. Services in biology include structural biology (https://www.jubilantbiosys.com/services/structural-biology/), in-vitro biology, DMPK (https://www.jubilantbiosys.com/services/dmpk/), in-vivo pharmacology and Toxicology. Further, Jubilant Biosys has integrated discovery expertise with a track record of working on over 80 programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases.

For more info: www.jubilantbiosys.com

For Business Development Contact: Ravichandran S bd@jubilantbiosys.com

About Jubilant Pharmova Limited:

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Limited) is a company engaged in pharmaceuticals, contract research and development services and proprietary novel drugs businesses. Pharmaceuticals business through Jubilant Pharma Limited Singapore (JPL) is engaged in manufacturing and supply of Radiopharmaceuticals with a network of 48 radiopharmacies in the US, Allergy Therapy Products, Contract Manufacturing of Sterile Injectables and Non-sterile products, APIs and Solid Dosage Formulations through six USFDA approved manufacturing facilities in the US, Canada and India. Jubilant Pharmova Limited has a team of around 5,800 multicultural people across the globe. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals companies globally.

For more information, please visit: www.jubilantpharmova.com.

For Business Development
Contact: Ravichandran S
Tags:Contract Research News
Location:San Diego - California - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Dignitas Digital PRs
Trending News
Most Viewed
Top Daily News

Like PRLog?
Click to Share